Our successful experiences with researching B-cell antigens, such as CD20, has led to exploration of additional B-cell surface proteins.3,4 CD79b, along with CD79a and a surface immunoglobulin, make up the BCR. CD79b, like CD20, is expressed on nearly all B-cell surfaces.1,2,5
CD79b can be internalized upon antibody binding.4,6 Due to this functionality, CD79b has the potential to selectively deliver molecules of interest to B cells found in non-Hodgkin lymphomas (NHLs) such as diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).4,5
CD79b-specific binding in B-cell malignancies4
In preclinical models, antibody binding to CD79b was shown to trigger the internalization of the BCR and bound antibody. This research established the potential for selective delivery of molecules of interest to B cells.4
Once internalized, the BCR complex and bound antibody are degraded, releasing the cytotoxic drug.4
Caballero A, Katkere B, Wen XY, Drake L, Nashar TO, Drake JR. Eur J Immunol. 2006;36:3131-3145. PMID: 17125144
Discover our broad range of antitumor modalities.
Learn more about the importance of cancer biomarkers.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.